# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

> **NCT06186414** · PHASE1 · RECRUITING · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 152 (estimated)

## Conditions studied

- Non-Muscle-Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** SIM0237
- **DRUG:** SIM0237 and BCG
- **DRUG:** SIM0237
- **DRUG:** SIM0237 and BCG

## Key facts

- **NCT ID:** NCT06186414
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2027-01
- **Final completion:** 2030-12
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186414, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06186414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*